whitepaper
Brochure: Custom Assay Development
The Custom Assay Development (CAD) program at DiscoverX develops tailor-made cell lines optimised for your needs, enabling you to jump start your drug discovery programs...
List view / Grid view
Drug Discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
article
Assays In-Depth Focus 2017
HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole animal screening assay formats. Horst Flotow, from Hit Discovery Constance, discusses the benefits and practicalities of, and recent progress in, whole animal screening. Madhu Lal-Nag, National Center for Advancing Translational Sciences, and Anton…
article
Whole animal screening: back to the future
High throughput screening (HTS) has become an integral and productive part of early-stage drug discovery, delivering hits that were the starting points for hit-to-lead programmes and resulting in a number of marketed drugs. HTS can be carried out in a number of formats, ranging from simple biochemical (target-based) to whole…
article
Product Hub: Flow cytometric screening assays in drug discovery
Flow cytometry is a laser-based technology – a powerful tool for drug discovery and the screening process and can be used in all settings, including research, clinical, pharmaceutical and biotechnology. The increasing capabilities of flow cytometers make their incorporation into drug development and screening optimal...
webinar
Vertical integration of CRISPR/Cas9 in drug discovery
10 February 2017 | By Charles River
In this webinar, Charles River discuss the utilisation of CRISPR/Cas9 technology in drug discovery, with an emphasis on generation of in vitro models for high-throughput screening, and creating new mouse models...
news
Lorenz Mayr joins Drug Discovery 2017 speaker lineup
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
news
Update on Charles River’s collaboration with Moderna Therapeutics
Charles River Laboratories has provided a progress update related to its support of Moderna Therapeutics’ nonclinical discovery and development efforts...
news
BenevolentAI becomes first AI company to appoint a Chief Medical Officer
BenevolentAI is the first AI company to have a CMO on its staff.
news
Chronos and Aptuit partner up for addictive behaviour programmes
The companies will work together on integrated drug discovery - medicinal and computational chemistry, biology and DMPK - to optimise Chronos’ selective orexin 1 antagonists that have shown promise in treating addiction.
news
Mission Therapeutics appoints Colin Goddard as Chairman
Mission Therapeutics have appointed Dr Colin Goddard as non-executive Chairman, effective January 1st 2017.
article
Valid biomarker signatures from liquid biopsies – how to standardise NGS
The advent of next-generation sequencing (NGS) techniques has revolutionised transcriptomics research and opened numerous avenues for scientific and clinical applications. While reverse transcriptase quantitative real-time polymerase chain reaction (RT-qPCR) is still considered the gold standard of gene expression analysis, its high throughput, single-nucleotide resolution and ever-plummeting costs have made NGS…
article
Versatile applications of next-generation sequencing in pharmaceutics
Next-generation sequencing (NGS) technologies hold great promise for unravelling the mysteries of biological systems, with the advent of DNA sequencing methods having greatly accelerated biomedical research, gaining broad applicability in disease diagnosis and therapeutics in recent years...
product
DiscoverX In Vitro Pharmacology Services – Simplify Your Drug Discovery Workflow
21 October 2016 | By DiscoverX Corporation
Monitoring cellular drug penetration and drug-target interaction enables assessment of compound efficacy and confirmation of mode of action...
news
Charles River Laboratories acquires Agilux Laboratories, Inc.
13 October 2016 | By Charles River Laboratories
Enhances Charles River’s early-stage capabilities in bioanalytical services...
